编号：2026—001 证券代码：301367 证券简称：瑞迈特 北京瑞迈特医疗科技股份有限公司 投资者关系活动记录表 1、公司的核心竞争力主要体现在哪些方面？ 一方面，公司聚焦呼吸健康领域 20 多年，深刻理解全球医疗 器械市场监管法规，拥有遍布全球的经销网络，是第一家无创呼 吸机产品通过美国 FDA 认证的国内上市公司，销往全球 140 多个 国家和地区，公司 2008 年取得 CE 认证，2012 年取得美国 FDA 认证，已进入美国、德国、英国、法国、意大利等国家的医保市 场，具备出色的全球市场进入能力。 其次，拥有专业成熟的知识产权部门，在全球主流市场及多 个国家针对产品均有专利及商标布局，为公司海外市场奠定坚实 基础。 | □ | 特定对象调研 分析师会议 □ | | --- | --- | | 投资者关系活动 □ | 媒体采访 □ 业绩说明会（电话形式） | | 类别 □ | 新闻发布会 √ 路演活动 | | □ | 现场参观 | | □ | 其他 | | 参与单位名称 | 详见附件清单 | | 时间 2026 | 年 月 日 2 26 | | 地点 上海 | | | 上市公司接待人 | 副总经 ...

Core Viewpoint - The company, 瑞迈特, is adjusting its investment structure for certain fundraising projects and extending the timelines for project completion, which aims to enhance the efficiency of fund utilization and optimize resource allocation [2][3]. Group 1: Company Performance - As of February 4, 2026, 瑞迈特's stock closed at 83.65 yuan, with an increase of 1.14% and a turnover rate of 1.01%, totaling a trading volume of 7,097 hands and a transaction amount of 58.92 million yuan [1]. - On the same day, the net outflow of main funds was 202.4 thousand yuan, while retail investors saw a net inflow of 176.79 thousand yuan [4]. Group 2: Corporate Announcements - On February 3, 2026, 瑞迈特's board of directors approved adjustments to the internal investment structure of certain fundraising projects, including increasing marketing and research and development investments while reducing expenditures on channel construction and equipment [2][3]. - The expected completion dates for several projects, including the annual production of 300,000 ventilators and 3.5 million sets of accessories, have been postponed to December 31, 2027, while the medical equipment research and development center project has been extended to December 31, 2026 [2][3].

Core Viewpoint - The domestic market for sleep breathing machines is still a blue ocean, with leading companies like Ruimai Te and Yuyue Medical showing significant strength in this niche sector [1][3][17]. Group 1: Market Overview - The market for sleep breathing machines is expanding due to increasing awareness of sleep-related health issues, particularly obstructive sleep apnea (OSA) [1][3]. - Ruimai Te ranks first in China and second globally in market share for home breathing machines, indicating strong competitive positioning [3][17]. - The company has seen a surge in consumer interest, with nearly half of the population starting to explore and purchase these devices online [3][17]. Group 2: Company Performance - Ruimai Te's stock price has increased by approximately 29% in 2025, reversing a three-year decline, with a peak above 100 yuan before stabilizing around 80 yuan [4][18]. - The company reported a revenue of 2.66 billion yuan in Q1 2025, a 38.11% increase year-on-year, and a net profit of approximately 601.9 million yuan, up 44.11% [4][18]. - For the first nine months of 2025, Ruimai Te achieved a revenue of 5.21 billion yuan, a 39.07% increase, with consumables revenue growing by 27.26% [23]. Group 3: Product Innovation - Ruimai Te has introduced advanced home breathing machines equipped with a smart algorithm that can accurately identify various respiratory events and adjust pressure in real-time [24][25]. - The company’s G3X model has received FDA approval and is expected to meet the needs of high-end customers in North America, contributing to a 133.85% increase in revenue from the U.S. market [5][19]. - The smart algorithm enhances user experience by synchronizing with the user's breathing rhythm, providing a comfortable treatment experience [24][25]. Group 4: Competitive Landscape - Yuyue Medical is a key competitor in the market, offering various models of non-invasive breathing machines, including continuous positive airway pressure (CPAP) devices [11][27]. - Both companies are engaged in healthy competition, driving growth in the medical device sector, with a focus on product effectiveness and user comfort [28]. - The market is characterized by a growing number of manufacturers, but only Ruimai Te and Yuyue Medical are publicly listed, indicating a concentrated competitive environment [28].

Group 1: Company Overview - The company was established in 2003 and launched its first multi-channel sleep monitor in the same year. The first CPAP sleep machine was introduced in 2007, and the company received CE certification in 2008 and FDA certification in 2012. It successfully listed on the Shenzhen Stock Exchange in 2016 [2]. - The company focuses on providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management, and is a leading domestic enterprise in home non-invasive ventilators and masks [2]. - As of June 30, 2025, the company holds 666 valid domestic patents, including 116 invention patents, 404 utility model patents, and 146 design patents. It also has 266 overseas patents, including 45 in the USA and 38 in Europe [3]. Group 2: Market Performance - In the US market, a new noise-free breathing machine began mass entry in July 2025, with significant sales growth observed in the third quarter. The acquisition of a new medical reimbursement code is expected to further boost sales [4]. - The European market has completed the construction of a cloud database platform, connecting over 1,000 primary and secondary agents, which is anticipated to drive growth by transitioning from non-mainstream to mainstream medical insurance markets [4]. Group 3: Sales Strategy and Product Development - The company initiated a shift from online distribution to direct sales at the end of September 2025, with expected gradual impacts on performance starting in the fourth quarter. The new model is projected to enhance gross margins and contribute to net profits [5]. - The portable oxygen concentrator (POC) has completed domestic registration, and a small non-invasive breathing machine has also been registered, which is expected to provide a continuous revenue increase domestically [5]. Group 4: Supply Chain and Cost Management - The company has largely achieved localization of core components, ensuring supply chain security and cost advantages. Future efforts will focus on optimizing domestic industrial chain collaboration to enhance business stability and risk resistance [6]. - The improvement in gross margins is attributed to effective cost control and an increase in the proportion of higher-margin consumables, with a stable upward trend expected in the future [7].

Core Insights - BMC瑞迈特 has been awarded the "Best Industry Breakthrough Brand" at the 2025 EDGE AWARDS for its continuous innovation and outstanding performance in the respiratory health sector [1] - The award signifies BMC瑞迈特's position as a value leader in the respiratory health market, combining technical strength and brand influence [1] Financial Performance - For the first three quarters of 2025, BMC瑞迈特 reported a revenue of 808 million yuan, representing a year-on-year increase of 34.24% [1] - The net profit attributable to shareholders reached 180 million yuan, with a year-on-year growth of 43.87%, indicating sustained growth in both revenue and profit [1] - The gross margin in the domestic market improved by 14.57% year-on-year and 11.63% quarter-on-quarter [1] - Revenue in the U.S. region saw a significant year-on-year increase of 63.46% and a quarter-on-quarter increase of 52.28% [1] Market Expansion - BMC瑞迈特's revenue in the U.S. for the first three quarters grew by 133.85% year-on-year, showcasing strong market expansion [2] - The company has developed a smart respiratory algorithm that accurately identifies 10 types of sleep breathing events, enhancing treatment effectiveness and user comfort [2] - BMC瑞迈特's home respiratory machines are equipped with a "Respiratory Health Management Cloud" that generates sleep reports and allows real-time data sharing with healthcare providers [2] Product Innovation - BMC瑞迈特 has launched new products such as smart mobile oxygen therapy devices and nebulizers, expanding its product matrix to cover multiple health management scenarios [2] - The company aims to establish itself as a "global respiratory health management preferred platform" through continuous technological innovation and market expansion [3] Global Presence - BMC瑞迈特's products have received certifications from multiple countries, including the U.S. FDA and EU CE, and are sold in over 140 countries and regions [3][5] - The company ranks second globally and first in China in terms of home respiratory machine sales, with cumulative sales exceeding 3 million units as of January 31, 2025 [5] - BMC瑞迈特 has established subsidiaries in various locations, including Tianjin, Dongguan, Xi'an, Shenzhen, Hong Kong, and France, employing over 900 people [5]

Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established in 2003 and launched its first multi-channel sleep monitor in the same year. The first CPAP sleep machine was introduced in 2007, followed by CE certification in 2008 and FDA certification in 2012. The company was successfully listed on the Shenzhen Stock Exchange in 2016 [2][3]. - The company focuses on providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management. It is a leading domestic manufacturer of non-invasive ventilators and masks, with products certified by NMPA, FDA, CE, and others [2][3]. Research and Development - As of June 30, 2025, the company holds 666 valid domestic patents, including 116 invention patents, 404 utility model patents, and 146 design patents. It also has 266 overseas patents, including 45 in the U.S. and 38 in Europe [3]. Market Performance - The new noise-free cotton ventilator has been entering the U.S. market since July 2025, with significant sales growth observed in the third quarter. The acquisition of a new medical reimbursement code is expected to further boost sales [4]. - The company transitioned from an online distribution model to a direct sales model in September 2025, with anticipated improvements in gross margins and net profits starting in the fourth quarter [5]. Investment Strategy - The company invested in Shenzhen Deda Xing Drive Technology Co., Ltd., a leading provider of precision motors and solutions in AI, robotics, and medical fields. This investment aims to secure the supply of core components and enhance the company's competitiveness [6]. Market Share - According to data from Sullivan, the company's home-use non-invasive ventilators hold a global market share of 12.4%, ranking second, while its domestic market share is 30.6%, ranking first among domestic brands. Future plans include strengthening brand building and optimizing channel management to increase market share [6].

Core Insights - BMC瑞迈特 is transitioning from a single supplier of respiratory devices to a comprehensive health management service provider for chronic respiratory diseases, focusing on technology and market demand for strategic upgrades [1][9] - The company has established itself as the second-largest global provider and the largest in China for respiratory health management solutions, with over 20 years of experience in the field [1][2] Technology and Innovation - BMC瑞迈特 holds 932 domestic and international patents, with over 90% concentrated in the sleep respiratory field, showcasing its long-term technological accumulation and industry leadership [2][3] - The company has successfully developed domestic production capabilities for key components, enhancing product performance and supply chain stability, which benefits the entire respiratory device industry [4] - BMC瑞迈特's unique high-flow intelligent airflow technology adjusts oxygen flow based on patient breathing, improving comfort and reducing oxygen consumption [4] Market Position and Performance - The company has sold over 3 million respiratory machines and 10 million masks, with a strong reputation and user recognition contributing to its growth [6] - Following the Philips recall incident in 2021, BMC瑞迈特 rapidly increased production capacity and filled market gaps, leading to significant sales growth [6] - In Q3 2025, the company reported revenues of 264 million yuan, a 20.22% increase year-on-year, and a net profit of 49 million yuan, up 48.61% year-on-year, continuing its strong performance throughout the year [6] Strategic Upgrades - The company rebranded from "怡和嘉业" to "瑞迈特" to align its trademark with its corporate identity, enhancing brand recognition in the domestic market [7] - BMC瑞迈特 has developed a global operational system, with localized strategies in the US, Europe, and India to cater to different market needs [8] Future Development - The company aims to build a comprehensive ecosystem for respiratory health management, transitioning from a product supplier to a full-scenario solution provider [9][10] - Future growth will focus on deepening overseas market engagement and enhancing domestic brand building, with new product launches expected in the coming years [10]

Core Insights - BMC瑞迈特 is transitioning from a single supplier of respiratory devices to a comprehensive health management service provider for chronic respiratory diseases, focusing on technology and market demand for strategic upgrades [1][6] - The company has established itself as the second-largest global provider and the largest in China for respiratory health management solutions, with over 20 years of experience in the field [1][2] Technology and Innovation - BMC瑞迈特 holds 932 domestic and international patents, with over 90% concentrated in the sleep respiratory field, showcasing its technological leadership [2] - The company has developed a domestic supply chain for critical components, enhancing product performance and supply chain stability, which benefits the entire respiratory device industry [3] - BMC瑞迈特 has created the largest domestic respiratory health management cloud platform, leveraging patient data for potential applications in disease prediction and treatment optimization [3] Market Position and Growth - The company has sold over 3 million respiratory devices and 10 million masks, with a strong reputation and user recognition contributing to its growth [4] - Following the Philips recall incident in 2021, BMC瑞迈特 rapidly increased production capacity and filled market gaps in the U.S., leading to significant sales growth [4][5] - In Q3 2025, the company reported revenues of 264 million yuan, a 20.22% increase year-on-year, and a net profit of 49 million yuan, up 48.61% [5] Strategic Upgrades - The company rebranded from "怡和嘉业" to "瑞迈特" to align its trademark with its corporate identity, enhancing brand recognition in the domestic market [5] - BMC瑞迈特 has established a global operational framework, including partnerships in the U.S., a subsidiary in France, and service centers in India, to cater to diverse market needs [6] Future Outlook - The company aims to build a comprehensive ecosystem for respiratory health management, focusing on prevention and treatment, with a projected market size in the hundreds of billions [6][7] - BMC瑞迈特 plans to enhance its core products while expanding into new areas such as oxygen therapy and chronic disease rehabilitation, aiming for significant growth in the next three years [7] - The long-term vision is to become the preferred platform for global respiratory health management, integrating data and resources to connect patients, manufacturers, and healthcare providers [7]

Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established in 2003 and launched its first multi-channel sleep monitor in the same year [2] - The company specializes in providing comprehensive treatment solutions for OSA and COPD patients, covering diagnosis, treatment, and chronic disease management [2] - It is a leading domestic enterprise in home non-invasive ventilators and masks, being the first domestic company to have non-invasive ventilator products approved by the FDA [2] - As of June 30, 2025, the company holds 666 valid domestic patents, including 116 invention patents and 404 utility model patents [3] Market Performance - The new noise-free cotton ventilator has shown significant sales growth in the U.S. market since its launch in July 2025, with a noticeable increase in sales levels in the third quarter [4] - The company has engaged over 1,000 primary and secondary agents in Europe, facilitating a transition from non-mainstream to mainstream insurance markets, which is expected to drive growth [5] Consumables Business - The consumables segment has maintained stable growth due to high usage frequency and profit margins, supported by strategic initiatives in various markets: - In the U.S., a consumables team was established in 2023, implementing active marketing strategies and distributing masks to sleep monitoring institutions to enhance brand recognition [6] - In Europe, a data-oriented subsidiary was established in France to address local insurance reimbursement issues and attract more agents [6] - In the domestic market, increasing awareness of chronic diseases is driving market penetration and growth in the number of ventilators [6][7] Production and Supply Chain - The company operates two manufacturing plants in Dongguan and Tianjin, with production capacity dynamically adjusted based on market demand [7] - The localization of core components has been largely achieved, ensuring supply chain security and cost advantages [7] - Future plans include optimizing domestic supply chain collaboration to enhance business stability and core competitiveness [7]

Company Overview - Beijing Ruimait Medical Technology Co., Ltd. was established in 2001 and launched its first multi-channel sleep monitor in 2003. The first CPAP sleep respirator was released in 2007, and the company received CE certification in 2008. In 2022, the company successfully listed on the Shenzhen Stock Exchange's Growth Enterprise Market [2][3]. - The company focuses on providing comprehensive treatment solutions for OSA and COPD patients, covering the entire cycle from diagnosis to treatment and chronic disease management. It is a leading domestic enterprise in home non-invasive ventilators and masks, with products sold in over 100 countries [2][3]. Research and Development - As of June 30, 2025, the company holds 666 valid domestic patents, including 116 invention patents, 404 utility model patents, and 146 design patents. It also has 266 overseas authorized patents, including 45 in the U.S. and 38 in Europe [3]. Financial Performance - The gross profit margin for Q3 2025 was 52.79%, an increase of 2.47% compared to the same period last year. The domestic gross profit margin increased by 14.57% year-on-year and by 11.63% compared to Q2 2025 [4]. - The company has initiated a shift from online distribution to direct sales as of September 2025, with expected gradual improvements in e-commerce gross profit margins starting from Q4 2025 [4]. Product Development - The new noise-free cotton respirator has been entering the U.S. market since July 2025, with significant sales growth observed in Q3. The acquisition of a medical reimbursement code is expected to further boost sales volume [5]. - The portable oxygen concentrator (POC) has completed domestic registration, and the small non-invasive respirator has also been registered, which is anticipated to contribute to domestic revenue growth [4]. Strategic Investments - The company has invested in Shenzhen Deda Xing Drive Technology Co., Ltd., a leading provider of precision motors and solutions, to ensure the stability of core component supplies and enhance its core competitiveness [6]. - The company is actively exploring the integration of AI technology in the medical field, focusing on improving service efficiency and device detection capabilities [6]. Investor Relations - The investor relations activity took place from October 30 to October 31, 2025, with participation from various investment institutions, including China Europe Fund and China Postal Fund [7].